From: Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
Factor | Cost-effectiveness ratio ($/QALY gained) |
---|---|
Base case analysis | 3,016 |
Simulation model | Â |
Log-normal | 2,874 |
Weibull | 3,341 |
Recurrence rate (95% CI: 30.5% - 38.8%) | 2,446 ‒ 3,891 |
Utility | Â |
Remission after surgery (95% CI: 0.788 - 0.898) | 2,825 ‒ 3,231 |
Metastasis (95% CI: 0.231 - 0.473) | 2,998 ‒ 3,032 |
QALY gained (95% CI: 0.48 – 1.96) | 1,901 ‒ 7,696 |
Recurrence cost (95% CI: $2,032 - $2,422) | 2,834 ‒ 3,149 |
End of life cost (95% CI: $3,997 - $4,766) | 2,682 ‒ 3,302 |
Exclusion of end-of-life costs due to gastric cancer | 3,677 |
S-1 cost (95% CI: $4,322 - $4,772) | 2,810 ‒ 3,173 |
Total cost difference (95% CI: $2,911 - $4,512 ) | 2,347 ‒ 3,638 |